Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017

New Software Simplifies Performing and Analyzing Dissolution via HPLC

By BiotechDaily International staff writers
Posted on 22 May 2013
Image: The Agilent LC Dissolution Software module (Photo courtesy of Agilent Technologies).
Image: The Agilent LC Dissolution Software module (Photo courtesy of Agilent Technologies).
ADVERTISEMENT
SARTORIUS AG
A new software module simplifies the quantification and reporting of dissolution samples analyzed by HPLC, maximizing the user's investment in dissolution apparatus, liquid chromatographs, and informatics.

Agilent Technologies Inc. (Santa Clara, CA, USA) now offers the new “LC Dissolution Software,” an add-on module for use with the ChemStation Edition of the Agilent OpenLAB Chromatography Data System. Once dissolution samples have been collected, they are loaded into the chromatograph and analyzed. The LC Dissolution Software module automates the setup of the chromatograph, incorporates the dissolution methodology, performs the sample analysis, and generates the final reports. Real-time views of the dissolution profile of all active ingredients are available as the analysis progresses.

"Customers can maximize their current workflow by integrating dissolution with LC analysis using LC Dissolution Software," said Allan Little, Agilent director of marketing for dissolution systems; "This software eliminates the need to export data to a spreadsheet and thus ensures the integrity and security of dissolution analysis data, all in a 21 CFR Part 11 environment."

Additional key product features include existing chromatographic methods that easily integrate for automatic generation of analysis sequences, sequence generation independent of hardware, and full utilization of all Agilent LC ChemStation software capabilities.

Related Links:

Agilent Technologies
LC Dissolution Software



Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.